ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
India’s Sun Pharmaceutical Industries will buy the 34% of shares in Taro Pharmaceutical Industries that it does not already own. Sun has been trying to acquire Israel-based Taro since late 2011. Taro accepted the deal when Sun raised its bid by 61% to $39.50 per share, or about $600 million in total. Taro sells prescription drugs, over-the-counter drugs, and active pharmaceutical ingredients. Sun manufactures APIs and generic drugs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter